Archive: 2020

20

Nov2020

Long-Term Follow-Up from AMPECT, an Open-Label Phase 2 Registration Trial of nab-Sirolimus for Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)

0  
November 20, 2020

25

Jun2020

Aadi Bioscience Initiates Rolling Submission of NDA to FDA for nab-sirolimus (ABI-009, FYARRO™) for the Treatment of Advanced Malignant PEComa

0  
Rolling submission of U.S. FDA New Drug Application initiated Long-term follow-up data released at ASCO 2020 for AMPECT study Independent reviewed ORR of 39% Long-term, durable ongoing responses with half the responders having ongoing response duration of 25.8 months or longer Exploratory analysis in patients with TSC2 mutated tumors show ... Read More
June 25, 2020

20

Jun2020

Long-term follow-up for duration of response (DOR) after weekly nab-sirolimus (ABI-009) in patients with advanced malignant perivascular epitlhelioid cell tumors (PEComa): Results from a registrational open-label phase 2 trial, AMPECT

0  
June 20, 2020

20

Jun2020

Phase I results from a phase 1/2 multi-center study of nab-sirolimus combined with mFOLFOX6+bevacizumab (FB) as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss

0  
June 20, 2020

01

Jan2020

x

0  
David Dornan, PhD
January 1, 2020